LVGN3616 + LVGN6051 + bevacizumab + cyclophosphamide

This is a combination regimen consisting of two investigational monoclonal antibodies, LVGN3616 and LVGN6051, together with the approved drugs bevacizumab and cyclophosphamide. LVGN3616 is a programmed cell death protein 1 (PD-1) receptor inhibitor monoclonal antibody developed by Lijin Biomedical Technology (Lyvgen Biopharma), currently in phase 1 clinical trials for metastatic solid tumors[8]. LVGN6051 (also known as exlinkibart) is a conditional 4-1BB agonistic monoclonal antibody designed for selective activation in the tumor microenvironment via Fcγ-receptor IIB binding, aiming to enhance antitumor immune responses[3][4][5]. Bevacizumab is an anti-vascular endothelial growth factor A (VEGF-A) humanized monoclonal antibody that inhibits angiogenesis and is approved for various cancers. Cyclophosphamide is an alkylating agent used as chemotherapy. This combination aims to leverage immune checkpoint inhibition (PD-1 blockade), T cell costimulation (4-1BB agonism), antiangiogenic therapy, and cytotoxic chemotherapy to treat advanced or metastatic solid tumors[8][2].

Other names

cyclophosphamide